Category: Publications 19 May 2021
Patient safety is paramount in drug trials
In a recent article in the New Scientist clinical trials supplement Dr Jorg Taubel, Scientific Lead at Richmond Research Institute, highlights the importance of reducing the risk to patients in phase I clinical trials.
As medicines become more personalised it will become necessary to conduct phase I trials directly with the target population. This must be approached with caution and improvements to phase I to trial design must be made before transferring the well-established healthy volunteer tool kit to patients who will often have complicated medical histories.
The drug action must be fully understood before conducting first in human trials.